Daguang Wang combines expertise in neuroscience discovery with board-level leadership experience. Before moving into venture investment, he spent more than 20 years in the biotech and pharmaceutical industry with Amgen, Memory Pharmaceuticals, PsychoGenics, EMD Serono and Sanofi. Dr. Wang started his career as an R&D scientist in neuroscience, before moving to business development and external innovation with a focus on neuroscience, multiple sclerosis and rare diseases. He was global lead of business development and external innovation for neuroscience at Sanofi before joining Yonjin Capital in 2018. He serves on the boards of multiple start-up biotech companies.

This website uses cookies to ensure you get the best experience on our website. Get more details by clicking on the Button below.